Abstract
Complications of long-term linezolid administration include anemia and thrombocytopenia. A recent report has suggested that pyridoxine may prevent myelosuppression. Pyridoxine was administered to 24 patients with bone infections who were being treated with linezolid. Thrombocytopenia occurred in 11 patients (45.8%), and anemia occurred in 6 (25%). We concluded that treatment wtih pyridoxine is unlikely to benefit patients who have been receiving linezolid for >2 weeks.
Publication types
-
Controlled Clinical Trial
MeSH terms
-
Acetamides / adverse effects*
-
Anemia / chemically induced
-
Anemia / drug therapy*
-
Anemia / epidemiology
-
Anti-Bacterial Agents / adverse effects*
-
Female
-
Humans
-
Incidence
-
Linezolid
-
Male
-
Middle Aged
-
Oxazolidinones / adverse effects*
-
Pyridoxine / therapeutic use*
-
Thrombocytopenia / chemically induced
-
Thrombocytopenia / drug therapy*
-
Thrombocytopenia / epidemiology
Substances
-
Acetamides
-
Anti-Bacterial Agents
-
Oxazolidinones
-
Linezolid
-
Pyridoxine